

### SURVEY\* BACKGROUNDER

GSK, with input from the National Ovarian Cancer Coalition (NOCC) and the Ovarian Cancer Research Alliance (OCRA), commissioned the *Our Way Forward* survey, a national survey of patients and healthcare providers developed to better understand the unmet education and support needs of the advanced ovarian cancer community.

## ABOUT THE SURVEY

The *Our Way Forward* survey was conducted online in the U.S. by Harris Poll on behalf of GSK. Nearly 500 women living with ovarian cancer and oncologists who treat women with the disease participated in the survey.

A total of 254 ovarian cancer patients and 232 healthcare providers consisting of medical and gynecologic oncologists were surveyed between April 2017 and May 2017.

The survey was designed so that patient and physician respondents may identify opportunities for the development of educational and support tools to help this community.

## SURVEY INPUT FROM:



[ovarian.org](http://ovarian.org)

**Founded in 1991**, the mission of the NOCC is to save lives by fighting tirelessly to prevent and cure ovarian cancer, and to improve the quality of life for Survivors. Through national programs and local NOCC chapter initiatives, the NOCC's goal is to educate communities and increase awareness about the symptoms of ovarian cancer. The NOCC also offers information to assist newly-diagnosed patients, hope to Survivors, and support to caregivers. The NOCC is also committed to the advancement of ovarian cancer research, specifically in funding the Ovarian Cancer Dream Team with Stand Up To Cancer®.



**Ovarian Cancer Research Alliance** (OCRA) is the largest global organization dedicated to fighting ovarian cancer. OCRA advances research to prevent, treat and defeat ovarian cancer, supports women and their families before, during and beyond diagnosis, and works with all levels of government to ensure ovarian cancer is a priority. As the largest non-government funder of ovarian cancer research, OCRA invests in innovative, promising research. And OCRA is the voice for the ovarian cancer community: fighting for more resources and policies on Capitol Hill, helping future health professionals recognize the disease through our Survivors Teaching Students® program, providing hope and insight by pairing newly diagnosed patients with our Woman to Woman program and connecting survivors at our Ovarian Cancer National Conference. We are united to defeat ovarian cancer. [www.ocrahope.org](http://www.ocrahope.org)

# ABOUT OVARIAN CANCER

OVARIAN CANCER IS **THE FIFTH LEADING** CAUSE OF CANCER DEATH IN AMERICAN WOMEN.<sup>1</sup>



**>22,000** U.S. WOMEN

are projected to be diagnosed with ovarian cancer annually – many of whom will be diagnosed with advanced disease.<sup>2</sup>



**~85%** OF WOMEN

with advanced ovarian cancer will recur after treatment.<sup>3</sup>



With **each subsequent** treatment with a platinum-based chemotherapy regimen, progression-free survival generally gets **shorter** and response rates get **progressively smaller**.<sup>4</sup>



**>14K** WOMEN

will die of ovarian cancer in 2017.<sup>5</sup>

\* The Our Way Forward survey was conducted online in the U.S. by Harris Poll on behalf of GSK between April 13 and May 2, 2017, among 254 women 18+ years of age living in the U.S. who have been diagnosed with ovarian cancer. Survey respondents were selected from individuals who had agreed to participate in surveys through the Harris Poll and their partners or were recruited to participate by patient advocacy organizations, NOCC and OCRA. Results are not weighted and are therefore representative of only those surveyed. A parallel survey was conducted between April 17 and May 5, 2017, among 232 physicians who treat ovarian cancer patients in the U.S. consisting of 201 medical oncologists and 31 gynecologic oncologists. Survey respondents were selected from physicians who had agreed to participate in surveys through the Harris Poll and their partners. Weights for gender by years in practice and region were applied to align the data with the population parameters for medical oncologists and gynecologic oncologists, separately. A post weight was then applied to combine the two medical specialty groups in proper proportion for the total.

For more information on the *Our Way Forward* survey findings, visit [OURWAYFORWARD.COM](https://OURWAYFORWARD.COM)

## REFERENCES

1. Ovarian Cancer Statistics. Centers for Disease Control and Prevention. <https://www.cdc.gov/cancer/ovarian/statistics/>. Accessed August 2020.
2. Cancer Facts and Figures. American Cancer Society. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html>. Accessed August 2020.
3. Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer [published online August 5, 2012]. *Int J Surg Oncol*. 2012;2012:613980. doi:10.1155/2012/613980.
4. Luvero D, Milani A, and Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. *Ther Adv Med Oncol*. 2014 Sep;6(5):229–239.
5. A Snapshot of Ovarian Cancer. National Cancer Institute. <https://www.cancer.gov/research/progress/snapshots/ovarian>. Accessed August 2020.

Trademarks are property of their respective owners.



©2020 GSK or licensor.  
NRPCLSM200006 July 2020  
Produced in USA.